S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Repligen (RGEN) Stock Price, News & Analysis

$157.14
+0.08 (+0.05%)
(As of 04/19/2024 ET)
Today's Range
$156.33
$159.41
50-Day Range
$157.06
$208.42
52-Week Range
$110.45
$211.13
Volume
386,770 shs
Average Volume
441,287 shs
Market Capitalization
$8.77 billion
P/E Ratio
218.25
Dividend Yield
N/A
Price Target
$196.70

Repligen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
25.2% Upside
$196.70 Price Target
Short Interest
Bearish
9.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.54mentions of Repligen in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$5.04 M Sold Last Quarter
Proj. Earnings Growth
43.15%
From $1.46 to $2.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

107th out of 907 stocks

Biological Products, Except Diagnostic Industry

14th out of 149 stocks

RGEN stock logo

About Repligen Stock (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock Price History

RGEN Stock News Headlines

Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98
Positive Report for Repligen (RGEN) from Craig-Hallum
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Repligen Corporation Common Stock (RGEN)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
RBC Capital Remains a Buy on Repligen (RGEN)
Repligen Appoints Maggie A. Pax to Board of Directors
RGEN Apr 2024 150.000 call
Repligen Corp CEO Anthony Hunt Sells 16,707 Shares
Repligen Corp RGEN
Repligen Corp COO James Bylund Sells 4,373 Shares
Decoding Repligen Corp (RGEN): A Strategic SWOT Insight
Repligen Stock (NASDAQ:RGEN), Short Interest Report
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,783
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$196.70
High Stock Price Target
$220.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+25.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$41.58 million
Pretax Margin
10.04%

Debt

Sales & Book Value

Annual Sales
$638.76 million
Cash Flow
$3.03 per share
Book Value
$35.31 per share

Miscellaneous

Free Float
55,169,000
Market Cap
$8.77 billion
Optionable
Optionable
Beta
1.02

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

RGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price target for 2024?

9 brokerages have issued 12-month target prices for Repligen's stock. Their RGEN share price targets range from $165.00 to $220.00. On average, they predict the company's share price to reach $196.70 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2024?

Repligen's stock was trading at $179.80 on January 1st, 2024. Since then, RGEN shares have decreased by 12.6% and is now trading at $157.14.
View the best growth stocks for 2024 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGEN earnings forecast
.

How can I listen to Repligen's earnings call?

Repligen will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "3623615".

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.33. The biotechnology company earned $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a trailing twelve-month return on equity of 5.00%. The company's quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.68 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY24 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of $1.42-1.49 for the period, compared to the consensus EPS estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.60%), Artemis Investment Management LLP (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.19%), Congress Asset Management Co. MA (0.16%), Norden Group LLC (0.07%) and Azzad Asset Management Inc. ADV (0.04%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
This page (NASDAQ:RGEN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners